Relative bioavailability of Neoral versus Sandimmune in the presence of a P450IIIA and P-glycoprotein inhibitor

Transplant Proc. 1998 Aug;30(5):1664-5. doi: 10.1016/s0041-1345(98)00383-2.
No abstract available

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / antagonists & inhibitors*
  • Administration, Oral
  • Aryl Hydrocarbon Hydroxylases*
  • Biological Availability
  • Biotransformation
  • Cross-Over Studies
  • Cyclosporine / administration & dosage
  • Cyclosporine / blood
  • Cyclosporine / pharmacokinetics*
  • Cytochrome P-450 CYP3A
  • Cytochrome P-450 Enzyme Inhibitors*
  • Dosage Forms
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / blood
  • Immunosuppressive Agents / pharmacokinetics*
  • Male
  • Metabolic Clearance Rate / drug effects
  • Oxidoreductases, N-Demethylating / antagonists & inhibitors*
  • Protein Synthesis Inhibitors / pharmacology

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Cytochrome P-450 Enzyme Inhibitors
  • Dosage Forms
  • Immunosuppressive Agents
  • Protein Synthesis Inhibitors
  • Cyclosporine
  • Aryl Hydrocarbon Hydroxylases
  • Cytochrome P-450 CYP3A
  • Oxidoreductases, N-Demethylating